Researchers question recommendations to provide pneumococcal polysaccharide vaccination for all older adults and for younger adults with chronic diseases. Although pneumococcal polysaccharide vaccine ...

Physicians and health officials often turn to meta-analyses to provide them with a single source of authoritative information on the efficacy and effectiveness of PPV23. One of the most recent is a ...

Current Primary Outcome Measures •Relative risk of adverse events [ Time Frame: 2014-2018 ] -- the ratio of probability of adverse events occuring in the risk periods after vaccination with PCV10 or ...

Please provide your email address to receive an email when new articles are posted on . To avoid uncertainty, an expert recommends physicians understand each vaccine’s serotypes and which ones are ...

Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.

The 23-valent pneumococcal polysaccharide vaccine (PPV) has been available for a number of years and is recommended for high-risk categories. Relatively immunocompetent elderly people are not included ...

Human antibodies to bacterial polyaaccharides consist primarily of IgG and are largely restricted to the IgG2 subclass. We examined the ontogeny of the IgG subclass response to pneumococcal ...

BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical ...

Sixty-two infants and 31 toddlers were vaccinated with the tetravalent pneumococcal conjugate vaccine PncOMPC consisting of the capsular polysaccharide of pneumococcal types 6B, 14, 19F, and 23F ...

Please provide your email address to receive an email when new articles are posted on . Research has shown that bacteremic pneumococcal pneumonia may peak in late winter. According to the CDC, the ...

(RTTNews) - Sinovac Biotech Ltd. (SVA), a China-based biopharmaceutical company, said Wednesday that the China National Medical Products Administration or NMPA has approved and issued a product ...